Schrodinger Inc. (NASDAQ: SDGR) reported Q1 EPS of ($0.81), $0.17 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $58.6 million versus the consensus estimate of $48.12 million.

Outlook:

As of May 5, 2026, Schrödinger maintained its previously issued financial guidance for the fiscal year ending December 31, 2026:

ACV is expected to range from $218 million to $228 million, representing 10-15% growth over 2025.
Drug discovery revenue is expected to range from $55 million to $65 million.
Operating expenses are expected to be less than 2025.

For the second quarter of 2026, ACV is expected to range from $19 million to $23 million, exclusive of contribution ACV, compared to $23.3 million in the second quarter of 2025, which included $5.0 million of contribution ACV.

For earnings history and earnings-related data on Schrodinger Inc. (SDGR) click here.